BioArk Technologies
Private Company
Funding information not available
Overview
Founded in 2019 and based in Cambridge, USA, BioArk Technologies operates as a CRO with a focus on the complex challenges of gene editing and nucleic acid delivery. The company leverages its expertise to design and engineer DNA and RNA for partners targeting major therapeutic areas. Its business model is centered on providing research services and platform capabilities to biopharmaceutical companies, positioning it as an enabler in the rapidly growing gene therapy and biologics space. As a private, likely pre-revenue or early-revenue entity, BioArk's success is tied to its technological proficiency and its ability to secure strategic partnerships.
Technology Platform
Integrated platform for gene editing (e.g., CRISPR system design) and nucleic acid delivery (e.g., LNP, viral vector formulation) to engineer DNA and RNA constructs for therapeutic research.
Opportunities
Risk Factors
Competitive Landscape
BioArk competes with large, full-service CROs (e.g., Charles River, LabCorp) that have gene editing divisions, as well as specialized boutique firms focused on delivery (e.g., gene therapy CDMOs) or editing services. Differentiation relies on deep integrated expertise in both editing and delivery, and superior client service in a niche segment.